To validate these findings, an independent panel of short-term melanoma cell cultures (all tested between the third and fifth in-vitro passage), obtained from 23 BRAF-mutant metastatic specimens of patients not previously treated with target-specific inhibitors, was used to test responsiveness to the same set of inhibitors. Here, BRAF is linked to melanoma.